[October 19, 2017] |
|
AMRA and BioTelemetry Research Raise the Standard for Medical Imaging in NASH/NAFLD Clinical Trials
AMRA, the international leader in body composition analysis, and
BioTelemetry Research ("BTR"), a leading global imaging and cardiac core
lab, announced today the formation of an exclusive alliance for
non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis (NASH) clinical trials. This first-to-market partnership
will advance imaging science and benefit clinical trial sponsors in
several musculoskeletal and metabolic therapeutic areas.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171019006110/en/
In clinical studies, muscle and fat fractions have traditionally been
measured by scanning individual organs such as the liver, or particular
body regions such as the abdomen. Commonly, researchers would prefer to
scan the entire body in order to learn exactly where study participants
are losing or gaining muscle or fat mass. However, until now they have
been constrained by prohibitive costs and insufficiently precise
outcomes.
AMRA's body composition analysis service has introduced a new and better
paradigm where rapid, six-minute whole body MRI scans are transformed
into precise, three dimensional-volumetric fat and muscle measurements.
This standardized, automated method eliminates reader variability and
reduces processing costs. With those advancements, BioTelemetry Research
is able to provide clinical trial sponsors with new, high-value
information to about their drug compounds' efficacy and mechanisms of
action, including the identification of previously undetectable changes
within and beyond the liver.
Tommy Johansson, Chief Executive Officer of AMRA, commented,
"BioTelemetry Research is the ideal core lab to help us deliver this
enhanced value to clinicaltrial sponsors. They bring unique expertise
managing the protocol complexity, site training intensity and equipment
variability that are common to non-standard-of-care MRI trials." He
continued, "BioTelemetry was a leading pioneer in proton density fat
fraction (PDFF) analysis, and have analysed more liver fat cases, from
more sites, in more regions than any other group in industry. I am
excited to see where our partnership will take us."
BioTelemetry Research President and General Manager, Scott Satin, added,
"By employing AMRA's automated analysis, we are now able to efficiently
provide more actionable data to our pharmaceutical partners. Ordinarily,
a whole body MRI scan takes 10 to 15 minutes and produces hundreds of
images. Prior to AMRA, such analyses were infeasible in clinical trials
largely because of the time needed to label fat and muscle tissues
within every image. With those challenges eliminated, we can now help
sponsors assess the effects of their treatments more quickly and
completely."
Through collaboration with leading universities such as the University
of California, San Diego (UCSD) and the University of Westminster,
London, AMRA's technique has been proven to enable market-leading
accuracy and precision when measuring fat depots and muscle volumes, as
well as the fat infiltration of muscles and in organs. BioTelemetry has
the scientific expertise and operational experience to apply this
technique successfully in global clinical trials. Together, the alliance
is committed to accelerate the prevention and treatment of diseases such
as NAFLD and obesity.
-ENDS-
About AMRA AMRA is the
first in the world to transform images from a rapid, 6-minute whole body
MRI scan into precise, 3D-volumetric fat and muscle measurements. AMRA's
cloud-based analysis service offers precise, automated insights that
have far-reaching implications for the pharmaceutical industry, academic
R&D and, soon, clinical practice. AMRA was founded in 2010 as a spin-off
of the Center for Medical Image Science and Visualization (CMIV), the
Department of Biomedical Engineering (IMT) and the Department of
Medicine and Health (IMH) at Linköping University, Sweden. For more
information, visit www.amra.se.
About BioTelemetry BioTelemetry
Research is the clinical research division of BioTelemetry, Inc.,
(NASDAQ: BEAT) the leading wireless medical technology company focused
on the delivery of health information to improve quality of life and
reduce cost of care. The Company currently provides cardiac monitoring
services, original equipment manufacturing with a primary focus on
cardiac monitoring devices and centralized imaging and cardiac core
laboratory services. More information can be found at www.gobio.com/research.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171019006110/en/
[ Back To Mobile World Congress's Homepage ]
|